Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure

Not Recruiting

Trial ID: NCT01023178


To directly compare the safety (by laboratory evaluation) and efficacy (feminization and growth) of three commonly used estrogen preparations in adolescent patients with ovarian failure, either due to congenital causes (Turner syndrome) or medical therapies. We hypothesize that transdermal estrogen will have equivalent efficacy and a more favorable safety profile in comparison with conventional oral estrogen replacement.

Official Title

Comparison of Transdermal and Oral Estrogens in Adolescents With Ovarian Failure

Stanford Investigator(s)


Inclusion Criteria: in whom initiation of estrogen therapy has been recommended due to
ovarian failure

   - Outpatients

   - age >=12 years to 17.99 years old

Exclusion Criteria:

   - spontaneous menses

   - significant concurrent medical problem including:

   - Liver function tests (LFTs) 3 times normal

   - clotting disorder

   - ongoing cancer treatment


drug: 17beta Estradiol

drug: Conjugated estrogens

drug: 17Beta Estradiol - transdermal

drug: Progesterone, micronized

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sejal Shah